Abstract Library

#2914 Safety Profile and Adverse Events of Special Interest for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial

Introduction: The previously reported SANET-ep trial (NCT02588170) demonstrated surufatinib significantly improves progression-free survival (PFS) in patients (pts) with advanced extrapancreatic neuroendocrine tumors (epNETs) compared to placebo; median PFS (9.2 vs. 3.8 months; HR = 0.334, 95% CI 0.223 to 0.499, p<0.0001).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Li J

Authors: Li J, Xu J, Zhou Z, Bai C, Chi Y,

Keywords: extra-pancreatic, neuroendocrine tumors, safety,

#2744 Immediate Adverse Effects of Peptide Receptor Radionuclide Therapy (PRRT) Administration in Patients with Neuroendocrine Tumors (NETs): A Single Institution Review

Introduction: PRRT is an effective treatment for well-differentiated NET, but immediate adverse events during or shortly after administration of the treatment are not well defined.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wee C, Dundar A, Packard A, Kendi A, Eiring R,

Keywords: prrt, peptide receptor radionuclide therapy,

#2203 A Case of Rectal Abscess Emerged Immediately after Starting Chemotherapy with Everolimus and Required Surgical Drainage

Introduction: Everolimus is widely used for unresectable panNET. For its efficacy as an immunosuppressant, infectious adverse events are well-known.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Nakano K, Masui T, Yogo A, Uchida Y, Sato A,

Keywords: everolimus, infection, abscess, rectal abscess, surgery, drainage,

#2112 Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials

Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F,

Keywords: adverse events, everolimus, RADIANT-3, RADIANT-4, landmark analysis, mTOR inhibitors, targeted therapy, neuroendocrine tumors,

#2060 Peptide Receptor Radionuclide Therapy (PRRT) in 35 Patients with Metastatic Neuroendocrine Neoplasms (NENs): Overall Response and Toxicity

Introduction: Metastatic or inoperable NeuroEndocrine Neoplasms (NENs) are unresponsive to chemotherapy and targeted therapies. An emerging option is PRRT.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Liotsou T

Authors: Liotsou T, Stefanoyiannis A, Alexandraki K, Koumarianou A, Angelousi A,

Keywords: NENs, PRRT,